Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2023, to report its second quarter 2023 financial results and related presentations. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for comprehensive information on the company's performance. These documents, available on the company's website, are crucial for understanding BMY's operational and financial standing for the period. Investors should note that the press release and presentation include non-GAAP financial measures, with reconciliations provided in the press release. The company has furnished these documents under Items 2.02 and 7.01, meaning they are not considered officially "filed" for purposes of Section 18 of the Exchange Act but are important for understanding the company's disclosed results and forward-looking initiatives.
Key Highlights
- 1BMY released its second quarter 2023 financial results on July 27, 2023.
- 2The 8-K filing includes an Earnings Press Release (Exhibit 99.1) with detailed financial results.
- 3A Bristol Myers Presentation (Exhibit 99.2) covering financial and operating initiatives is also available.
- 4Both furnished documents contain non-GAAP financial information, with reconciliations provided in the Earnings Press Release.
- 5The information is furnished under Regulation FD and is not deemed "filed" for certain legal purposes.
- 6Investors are directed to the company's website for the webcast and presentation details.